Kidney Transplant Recipients Carrying the CYP3A4*22 Allelic Variant Have Reduced Tacrolimus Clearance and Often Reach Supratherapeutic Tacrolimus Concentrations

CYP3A4*22 is an allelic variant of the cytochrome P450 3A4 associated with a decreased activity. Carriers of this polymorphism may require reduced tacrolimus (Tac) doses to reach the target residual concentrations (Co). We tested this hypothesis in a population of kidney transplant recipients extracted from a multicenter, prospective and randomized study. Among the 186 kidney transplant recipients included, 9.3% (18 patients) were heterozygous for the CYP3A4*22 genotype and none were homozygous (allele frequency of 4.8%). Ten days after transplantation (3 days after starting treatment with Tac), 11% of the CYP3A4*22 carriers were within the target range of Tac Co (10–15 ng/mL), whereas among the CYP3A4*1/*1 carriers, 40% were within the target range (p = 0.02, OR = 0.19 [0.03; 0.69]). The mean Tac Co at day 10 in the CYP3A4*1/*22 group was 23.5 ng/mL (16.6–30.9) compared with 15.1 ng/mL (14–16.3) in the CYP3A4*1/*1 group, p < 0.001. The Tac Co/dose significantly depended on the CYP3A4 genotype during the follow‐up (random effects model, p < 0.001) with the corresponding equivalent dose for patients heterozygous for CYP3A4*22 being 0.67 [0.54; 0.84] times the dose for CYP3A4*1/*1 carriers. In conclusion, the CYP3A4*22 allelic variant is associated with a significantly altered Tac metabolism and carriers of this polymorphism often reach supratherapeutic concentrations.

[1]  D. Hesselink,et al.  Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks. , 2014, British journal of clinical pharmacology.

[2]  V. Haufroid,et al.  Impact of CYP3A4*22 Allele on Tacrolimus Pharmacokinetics in Early Period After Renal Transplantation: Toward Updated Genotype-Based Dosage Guidelines , 2013, Therapeutic drug monitoring.

[3]  G. Koren,et al.  CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients. , 2013, Pharmacogenomics.

[4]  D. Hesselink,et al.  Pharmacogenetics in Kidney Transplantation , 2012, Molecular Diagnosis & Therapy.

[5]  V. Haufroid,et al.  A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. , 2011, Clinical chemistry.

[6]  W. Sadee,et al.  Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs , 2011, The Pharmacogenomics Journal.

[7]  D. Hesselink,et al.  The Pharmacogenetics of Calcineurin Inhibitor–Related Nephrotoxicity , 2010, Therapeutic drug monitoring.

[8]  M. Loriot,et al.  Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing , 2010, Clinical pharmacology and therapeutics.

[9]  C. Staatz,et al.  Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part II , 2010, Clinical pharmacokinetics.

[10]  C. Staatz,et al.  Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I , 2010, Clinical pharmacokinetics.

[11]  Michael Oellerich,et al.  Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. , 2005, Clinical chemistry.

[12]  Ernest Hodgson,et al.  Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. , 2003, Pharmacogenetics.

[13]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[14]  M. Ingelman-Sundberg,et al.  Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region. , 1999, Biochemical and biophysical research communications.

[15]  U. Christians,et al.  Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[16]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.